CXCL10 and cancer: Treatment-driven ICD involves the activation of a cancer cell-intrinsic type I IFN response and consequent secretion of CXCL10 that mediates chemotactic effects of activating immune cells, including cytotoxic CD8+ T-cells and NK-cells, into the tumor microenvironment [19,45].